OMER News and Press, Omeros Corporation From 10/01/18

Omeros ( OMER -5.3% ) announces positive results from a Phase 2 clinical trial evaluating OMS721 in corticosteroid therapy-naive patients with immunoglobulin A (IgA) nephropathy. More news on: Omeros Corporation, Healthcare stocks news, Stocks on the move, Read more ...

-- Magnitude of Proteinuria Reduction Consistent With Previous Cohort -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the company’s ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases. The data are from study patients with i...

-- CMS’ Separate Payment for Cataract Surgery Drug Resumes Today -- Omeros Corporation (NASDAQ: OMER) announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company’s cataract s...

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Cantor Global Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, October 2, 2018 at 1:05 p.m. EDT. The p...